GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (FRA:OJU1) » Definitions » Retained Earnings

Oramed Pharmaceuticals (FRA:OJU1) Retained Earnings : €-143.54 Mil (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Oramed Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Oramed Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2024 was €-143.54 Mil.

Oramed Pharmaceuticals's quarterly retained earnings increased from Sep. 2023 (€-160.13 Mil) to Dec. 2023 (€-144.48 Mil) and increased from Dec. 2023 (€-144.48 Mil) to Mar. 2024 (€-143.54 Mil).

Oramed Pharmaceuticals's annual retained earnings declined from Aug. 2021 (€-97.62 Mil) to Dec. 2022 (€-153.95 Mil) but then increased from Dec. 2022 (€-153.95 Mil) to Dec. 2023 (€-144.48 Mil).


Oramed Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Oramed Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Retained Earnings Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.91 -78.26 -97.62 -153.95 -144.48

Oramed Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -155.49 -154.76 -160.13 -144.48 -143.54

Oramed Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Oramed Pharmaceuticals  (FRA:OJU1) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Oramed Pharmaceuticals (FRA:OJU1) Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Oramed Pharmaceuticals (FRA:OJU1) Headlines

No Headlines